{"id":"NCT00613106","sponsor":"Amgen","briefTitle":"Double-Blind Follow-on Safety Study of HZT-501 (Ibuprofen 800 mg/Famotidine 26.6 mg) in Subjects Who Have Completed Participation in HZ-CA-301 (NCT00450658) or HZ-CA-303 (NCT00450216)","officialTitle":"Double-Blind Follow-On Safety Study of HZT-501 (Ibuprofen 800 mg/Famotidine 26.6 mg)in Subjects Who Have Completed Participation in Horizon Protocol HZ-CA-301 (NCT00450658)or Horizon Protocol HZ-CA-303 (NCT00450216)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-09","primaryCompletion":"2008-10","completion":"2008-10","firstPosted":"2008-02-12","resultsPosted":"2011-06-17","lastUpdate":"2024-12-17"},"enrollment":179,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"PREVENTION"},"conditions":["Osteoarthritis","Rheumatoid Arthritis","Chronic Low Back Pain","Chronic Regional Pain Syndrome","Chronic Soft Tissue Pain"],"interventions":[{"type":"DRUG","name":"HZT-501","otherNames":[]},{"type":"DRUG","name":"Ibuprofen","otherNames":[]}],"arms":[{"label":"HZT-501","type":"EXPERIMENTAL"},{"label":"Ibuprofen","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to evaluate the safety of long-term treatment with HZT-501.","primaryOutcome":{"measure":"Number of Participants With Treatment Emergent Adverse Events","timeFrame":"28 weeks","effectByArm":[{"arm":"HZT-501 (Ibuprofen/Famotidine)","deltaMin":55,"sd":null},{"arm":"Ibuprofen","deltaMin":16,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.4228"}]},"eligibility":{"minAge":"40 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":1},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":132},"commonTop":["gastroenteritis viral","influenza","sinusitis","upper respiratory tract infection","viral upper respiratory tract infection"]}}